| Name | Title | Contact Details |
|---|
RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers. The highly fragmented global Healthcare IT and EMR market is expected to grow by 15% to $10 billion by 2015. Ambient believes there is a significant opportunity in this growing market to implement analytics based dashboard tools to reduce errors and improve efficiency. Our goal is supported by a $16 million CMS grant to deploy Ambient’s AWARE program in 3 hospitals starting September 2013. This software platform can be used in any data intensive hospital unit and is the perfect combination of “Big Data” and “Analytics”. Our analytical tools and suggested care checklists are unique to the current healthcare IT market. Ambient Clinical Analytics is supported financially by software license fees, SaaS, Cloud, and system integration revenue.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
Ideomed is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Grace Davison Discovery Sciences is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.